U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT06809491) titled 'One-year Recurrence-free Survival of Melanoma Patients Eligible for a Sentinel Lymph Node Biopsy' on Jan. 23.
Brief Summary: Melanoma is one of the most aggressive solid cancers, although mortality can be reduced with early treatment. Immunotherapy has transformed the prognosis of this pathology.
The sentinel lymph node technique is used to classify the severity of melanoma. It is proposed for melanomas with a Breslow thickness of 0.8 mm to 1 mm, and recommended for melanomas greater than 1 mm or with ulceration, whatever the Breslow index.
This technique is particularly useful for assessing pathology by detecting the presence of l...